Dr. Bou-Ghannam serves as the Chief Scientific Advisor at TriCelX, bringing a decade of clinical research experience in mesenchymal stem cell (MSC) therapeutics for regenerative medicine. She holds a PhD in Biomedical Engineering from the University of Utah, where she trained under Professor Teruo Okano, the esteemed father of cell sheet tissue engineering. Throughout her career, she has authored over 10 peer-reviewed publications demonstrating the clinical utility of MSCs for treating various complex fibrotic and degenerative diseases, including cardiomyopathy, liver fibrosis, and orthopedic defects.
Her original research focused on engineering MSCs to enhance their pro-regenerative and anti-inflammatory capacities, maximizing their ability to act as bioactive factor delivery depots upon transplantation. Dr. Bou-Ghannam was awarded a Whitaker International Fellowship to conduct translational stem cell research at Tokyo Women’s Medical University in Japan, where she extensively studied exosomes and developed robust methods for their production, isolation, and characterization.
She recently held the role of Cell Line Development Lead at a prominent company specializing in large-scale stem cell production, managing operations at scales up to 6,000 liters for commercial applications. Dr. Bou-Ghannam joins TriCelX to leverage her extensive experience in advanced biologics and their manufacturing to develop evidence-based medicines addressing unmet clinical needs and improving human health and performance.